102Indexed trials
Market Rank #24 · Evidence Tier A
Czechia
Neuroscience Intelligence
Czechia neuroscience intelligence: 102 indexed trials, 6 institutions, research score 31.08.
26Recruiting
6Research institutions
31.1Research score
Evidence profile
67Sponsors
22Disease areas
0Institution works
0Institution citations
Model signals
Opportunity 31 · ML priority 31 · Confidence 100 · Evidence 31.1
These are comparative evidence signals. They do not represent a guarantee of market size or commercial outcome.
Leading disease areas
parkinsons18trials
epilepsy18trials
alzheimers9trials
multiple_sclerosis7trials
other_neurology6trials
pain_neuropathy4trials
stroke4trials
depression3trials
migraine_headache3trials
bipolar_disorder3trials
Leading indexed sponsors
Merck Sharp & Dohme LLC7trials
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.4trials
Boehringer Ingelheim4trials
Masaryk University4trials
UCB Pharma4trials
Novo Nordisk A/S3trials
Ipsen3trials
Eisai Limited3trials
Biogen3trials
AbbVie3trials